ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,515.89
0.12%
US Tech 100
19,490.00
0.06%
Dow Jones
39,339.80
0.02%
Brent Oil
86.515
0.08%
Bitcoin
60,482.56
-2.49%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. ImmunoPrecise Antibodies Ltd (IPA)

  7. ImmunoPrecise Antibodies Ltd (IPA) News

IPA

ImmunoPrecise Antibodies (IPA)

ImmunoPrecise Antibodies Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IPA
DateTimeSourceHeadlineSymbolCompany
06/27/20246:27PMBusiness WireImmunoPrecise nomme Kristin Taylor au poste de directeur financierNASDAQ:IPAImmunoPrecise Antibodies Ltd
06/27/20248:01AMBusiness WireImmunoPrecise Appoints Kristin Taylor as Chief Financial OfficerNASDAQ:IPAImmunoPrecise Antibodies Ltd
06/25/20247:55PMBusiness WireBioStrand, filiale d’IPA, et PGxAI annoncent un accord de collaboration stratégique visant à développer à l’aide de LENSai™ un modèle d’IA d’avant-garde pour les recommandations pharmacogénomiquesNASDAQ:IPAImmunoPrecise Antibodies Ltd
06/25/20247:02AMBusiness WireIPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™NASDAQ:IPAImmunoPrecise Antibodies Ltd
06/12/20241:01PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
06/12/20247:00AMBusiness WireImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ TechnologyNASDAQ:IPAImmunoPrecise Antibodies Ltd
06/12/20247:00AMBusiness WireBioStrand, filiale d’ImmunoPrecise Antibodies Ltd., reçoit le prestigieux prix Impact 2024 pour sa technologie LENSai™ révolutionnaireNASDAQ:IPAImmunoPrecise Antibodies Ltd
06/10/20242:23PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
06/10/202411:34AMBusiness WireBioStrand, filiale d’ImmunoPrecise Antibodies, annonce la disponibilité commerciale immédiate de son logiciel révolutionnaire doté d’une interface personnalisable pour la découverte de médicaments optimisée par l’IANASDAQ:IPAImmunoPrecise Antibodies Ltd
06/10/20247:15AMBusiness WireBioStrand, ImmunoPrecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug DiscoveryNASDAQ:IPAImmunoPrecise Antibodies Ltd
06/04/20245:01PMBusiness WireLa filiale d’IPA, BioStrand, annonce un LLM avancé pour les dossiers de santé électroniquesNASDAQ:IPAImmunoPrecise Antibodies Ltd
06/04/20244:11PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
06/04/20247:00AMBusiness WireIPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR)NASDAQ:IPAImmunoPrecise Antibodies Ltd
03/28/20242:35PMBusiness WireInterSystems et BioStrand, filiale d’IPA, collaborent au lancement de l’intégration innovante de la recherche vectorielle et de LENSai dans les applications de soins de santé pilotées par l’IANASDAQ:IPAImmunoPrecise Antibodies Ltd
03/28/20247:02AMBusiness WireInterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare ApplicationsNASDAQ:IPAImmunoPrecise Antibodies Ltd
03/20/20241:52PMBusiness WireIPA acquiert l'instrument Carterra LSA® pour améliorer la découverte d'anticorps et renforcer ses développements en matière d'IANASDAQ:IPAImmunoPrecise Antibodies Ltd
03/20/20247:02AMBusiness WireIPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI DevelopmentsNASDAQ:IPAImmunoPrecise Antibodies Ltd
03/14/20247:39PMBusiness WireIPA présente ses résultats financiers et les récents points forts de son activité pour le troisième trimestre de l’exercice 2024*NASDAQ:IPAImmunoPrecise Antibodies Ltd
03/14/20248:05AMBusiness WireIPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024*NASDAQ:IPAImmunoPrecise Antibodies Ltd
03/07/20243:24PMBusiness WireBioStrand, filiale d'IPA, annonce une avancée majeure dans les sciences du vivant avec son Advanced Foundation AI Model utilisant l'empilement LLM et la technologie HYFTNASDAQ:IPAImmunoPrecise Antibodies Ltd
03/07/202411:19AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
03/07/20247:02AMBusiness WireIPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT TechnologyNASDAQ:IPAImmunoPrecise Antibodies Ltd
03/04/20244:50PMBusiness WireL'IPA publiera ses résultats financiers et les faits marquants de sa récente activité pour le troisième trimestre de l'exercice 2024, le 14 mars 2024NASDAQ:IPAImmunoPrecise Antibodies Ltd
03/04/20248:01AMBusiness WireIPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024 on March 14, 2024NASDAQ:IPAImmunoPrecise Antibodies Ltd
02/23/20245:29PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
02/23/20245:26PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IPAImmunoPrecise Antibodies Ltd
02/15/20243:12PMEdgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:IPAImmunoPrecise Antibodies Ltd
01/10/20241:53PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:IPAImmunoPrecise Antibodies Ltd
01/10/20241:33PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:IPAImmunoPrecise Antibodies Ltd
12/14/20233:08PMBusiness WireIPA présente ses résultats financiers et les récents points forts de son activité pour le deuxième trimestre de l’exercice 2024*NASDAQ:IPAImmunoPrecise Antibodies Ltd
 Showing the most relevant articles for your search:NASDAQ:IPA

Your Recent History

BIT
S32515
Societe Generale Effekten
ASX
ARB
Arb
BIT
MLPD
Invesco Morningstar Us E...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved